Can‑Fite BioPharma Insider Buying Signals Long‑Term Confidence Amid Volatile Stock: CEO and Key Executives Stack Unvested Options as Patent Deal Fuels Optimism
Insider option holdings at Can‑Fite BioPharma reveal long‑term confidence, bolstered by a new obesity patent and strong IP—great insight for high‑risk biotech investors.
6 minutes to read